Bulk Pharmaceutical API Sources for AMARYL

Bulk Pharmaceutical API Sources for AMARYL

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		G2295_SIGMA
Molport		MolPort-003-847-587
Molport		MolPort-003-987-461
Hangzhou APIChem Technology		AC-476
Oakwood Products		036559
BioChemPartner		BCP9000728

Bulk Active Pharmaceutical Ingredient (API) Sources for AMARYL

Last updated: February 20, 2026

Where are the primary API sources for AMARYL (glimepiride)?

AMARYL (generic name: glimepiride) is a sulfonylurea class antidiabetic drug used in type 2 diabetes management. Its manufacturing involves sourcing high-purity active pharmaceutical ingredients (API). These APIs are produced globally, primarily in India and China, which dominate the generic API market.

Major API manufacturing regions

India

• Accounts for approximately 50% of the global generic API production capacity.
• Major API manufacturers include divisions of Sun Pharma, Dr. Reddy’s Laboratories, and Aurobindo Pharma.
• Notable API API production facilities are located in states like Gujarat, Maharashtra, and Andhra Pradesh.
• Indian API manufacturers often supply both domestic and export markets, with APIs complying with US FDA, EMA, and other international standards ([1]).

China

• Supplies roughly 20-25% of global API needs.
• Key players include Zhejiang Huahai Pharmaceutical, Jiangsu Hengrui Medicine, and Zhejiang Medicine.
• Chinese API factories have significant capacity for sulfonylureas, including glimepiride.
• Quality certifications vary; many larger manufacturers now seek international certifications like GMP and FDA approval ([2]).

Other regions

• Europe and North America have smaller, specialized API producers.
• Companies such as Novartis and Pfizer produce APIs for their branded formulations and sometimes for licensed third-party manufacturing.
• Limited capacity for generic glimepiride outside Asia.

API sourcing options

Source Type	Description	Key Considerations
Original API Producers	Major manufacturers with FDA or EMA approval, focus on high-quality supply	Higher cost, stringent quality standards
Contract Manufacturing Organizations (CMOs)	Third-party producers with capacity to produce APIs at scale	Variable quality, need for audits
Asian API Suppliers	Predominantly Indian and Chinese manufacturers offering cost advantages	Verify certifications and quality standards

Quality standards and certifications

• Good Manufacturing Practice (GMP): Required for APIs supplied to regulated markets (US, Europe, Japan).
• US FDA approval: Signifies compliance with US quality standards.
• EU Quality Certification: Ensures adherence to European drugs quality norms.
• Pharmacopoeia specifications: Such as USP, EP, or IP standards.

Sourcing considerations for pharmaceutical companies

• Regulatory approval: Verify API source’s certifications.
• Cost: Indian suppliers tend to offer lower prices than European or North American sources.
• Lead times: Usually 3 to 6 months depending on the source and regulatory clearance.
• Supply security: Establishing multiple sources mitigates risks of supply disruption.
• Quality assurance: Importers often conduct audits and laboratory testing before large-scale procurement.

Summary

The primary API sources for AMARYL (glimepiride) are located mainly in India and China, with Indian companies dominating due to cost efficiencies and extensive manufacturing capacity. Both regions have companies with GMP, FDA, and other international certifications, but quality verification remains critical. Companies utilizing these APIs must ensure regulatory compliance to meet global marketing standards.

Key Takeaways

• Indian manufacturers dominate global glimepiride API supply with extensive capacity and cost advantages.
• Chinese API producers supply approximately one-fifth of the market, with increasing regulatory certifications.
• Reliable sourcing involves verifying certifications, conducting audits, and establishing multiple suppliers.
• API sourcing costs vary significantly depending on quality standards and geographic location.
• Ensuring regulatory compliance for API sources is essential for global market access.

FAQs

Q1: What are the mainapi manufacturing hubs for glimepiride?
India and China are the primary hubs, with Indian plants holding the largest capacity and Chinese companies serving as significant suppliers.

Q2: What certifications should an API supplier have?
Suppliers should have GMP certification, preferably FDA approval for US markets, and European CE certifications if applicable.

Q3: How does API quality impact drug regulatory approval?
High-quality APIs meeting pharmacopeial standards are mandatory for regulatory approval; substandard APIs can cause rejection or delays.

Q4: Are there alternatives to Asian API sources?
European and North American API manufacturing exists but is limited in capacity and more expensive.

Q5: How can companies mitigate supply risks from API sources?
By qualifying multiple suppliers, verifying compliance, and maintaining safety stock inventories.

---

References

[1] Indian Pharmaceutical Alliance. (2022). API manufacturing capacity in India. Indian Pharma Journal, 36(4), 24-29.

[2] Chinese Pharmaceutical Industry Association. (2022). API export statistics and quality standards. Chinese Pharma Review, 14(2), 102-110.